Transcode Therapeutics Stock Performance
| RNAZ Stock | USD 8.05 0.35 4.17% |
The entity has a beta of 2.46, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Transcode Therapeutics will likely underperform. At this point, Transcode Therapeutics has a negative expected return of -0.47%. Please make sure to validate Transcode Therapeutics' mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and daily balance of power , to decide if Transcode Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Transcode Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (4.17) | Five Day Return 23.47 | Year To Date Return 128.05 | Ten Year Return (99.99) | All Time Return (99.99) |
Last Split Factor 1:33 | Last Split Date 2024-12-04 |
1 | TransCode Faces Delisting Risk, Seeks Shareholder Approval for Reverse Split RNAZ Stock News - StockTitan | 11/12/2024 |
2 | TransCode Therapeutics to conduct reverse stock split | 11/25/2024 |
3 | TransCode Therapeutics, Inc. Announces 8 Million Private Placement | 11/27/2024 |
4 | Why TransCode Therapeutics Stock Is Diving | 12/02/2024 |
5 | Peering Into TransCode Therapeuticss Recent Short Interest - Benzinga | 12/12/2024 |
6 | SABBY MANAGEMENT, LLC Acquires Shares in TransCode Therapeutics Inc - GuruFocus.com | 01/03/2025 |
7 | Transcode Therapeutics stock hits 52-week low at 3.20 - Investing.com | 01/13/2025 |
8 | How Is The Market Feeling About TransCode Therapeutics - Benzinga | 01/29/2025 |
| Begin Period Cash Flow | 5 M |
Transcode |
Transcode Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,700 in Transcode Therapeutics on November 2, 2024 and sell it today you would lose (895.00) from holding Transcode Therapeutics or give up 52.65% of portfolio value over 90 days. Transcode Therapeutics is currently does not generate positive expected returns and assumes 13.2696% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Transcode, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Transcode Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Transcode Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Transcode Therapeutics, and traders can use it to determine the average amount a Transcode Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0357
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RNAZ |
Estimated Market Risk
| 13.27 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.47 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Transcode Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Transcode Therapeutics by adding Transcode Therapeutics to a well-diversified portfolio.
Transcode Therapeutics Fundamentals Growth
Transcode Stock prices reflect investors' perceptions of the future prospects and financial health of Transcode Therapeutics, and Transcode Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Transcode Stock performance.
| Return On Equity | -10.49 | ||||
| Return On Asset | -2.08 | ||||
| Current Valuation | 3.88 M | ||||
| Shares Outstanding | 696.25 K | ||||
| Price To Book | 3.39 X | ||||
| EBITDA | (17.97 M) | ||||
| Net Income | (18.55 M) | ||||
| Cash And Equivalents | 13.45 M | ||||
| Cash Per Share | 1.04 X | ||||
| Total Debt | 450.57 K | ||||
| Current Ratio | 8.06 X | ||||
| Book Value Per Share | 2.62 X | ||||
| Cash Flow From Operations | (18.07 M) | ||||
| Earnings Per Share | 5,572 X | ||||
| Market Capitalization | 5.6 M | ||||
| Total Asset | 5.17 M | ||||
| Retained Earnings | (46.42 M) | ||||
| Working Capital | 964.85 K | ||||
About Transcode Therapeutics Performance
Evaluating Transcode Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Transcode Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Transcode Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 1.8 K | 1.6 K | |
| Return On Tangible Assets | (4.13) | (4.33) | |
| Return On Capital Employed | (13.30) | (12.63) | |
| Return On Assets | (4.13) | (4.33) | |
| Return On Equity | (13.00) | (12.35) |
Things to note about Transcode Therapeutics performance evaluation
Checking the ongoing alerts about Transcode Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Transcode Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Transcode Therapeutics generated a negative expected return over the last 90 days | |
| Transcode Therapeutics has high historical volatility and very poor performance | |
| Transcode Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (18.55 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Transcode Therapeutics currently holds about 13.45 M in cash with (18.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04. | |
| Latest headline from news.google.com: How Is The Market Feeling About TransCode Therapeutics - Benzinga |
- Analyzing Transcode Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Transcode Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Transcode Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Transcode Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Transcode Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Transcode Therapeutics' stock. These opinions can provide insight into Transcode Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.